Lung Biopsy Systems Market Trends

Growth Drivers

Growing Geriatric Population– The elderly population is more prone to chronic lung diseases and the rising number of elderly populations across the globe is estimated to drive lung biopsy systems market growth. According to estimates, the number of individuals in the world who are 60 or older will increase to over 2 billion by 2050.
Spiking Cases of COPD to Propel the Growth of the Market - COPD, a chronic obstructive pulmonary disease, is considered an inflammatory lung disease that is responsible for the interrupted airflow from the lungs and can result in the death of the affected person. COPD requires quick medical attention and early diagnosis to be cured thoroughly.

Challenges

Possibility of Side Effects Such as Blood Loss and Pneumonia– In some patients, a lung biopsy will cause side effects such as blood clots or blood loss, pain, discomfort, infection, and pneumonia. These are estimated to hamper the market growth in the coming years as per the market analysis.
Requirement of High Initial Investment
Lack of Skilled Medical Professionals

Lung Biopsy Systems Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	15.4%
Base Year Market Size (2023)	USD 3.46 Billion
Forecast Year Market Size (2036)	USD 22.28 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of lung biopsy systems is assessed at USD 3.94 Billion.

The lung biopsy systems market size was valued at USD 3.46 Billion in 2023 and is set to reach USD 22.28 Billion by the end of 2036, expanding at around 15.4% CAGR during the forecast period i.e., between 2024-2036. Higher prevalence of lung cancer across the globe and the growing inclination toward minimally invasive surgeries are the major factors driving the growth of the market.

North America industry is predicted to account for the largest share of 42% by 2036, impelled by growing research and clinical trials to test a new approach to treatment for lung cancer in the region.

Argon Medical Devices, Inc., Fujifilm Corporation, Cardinal Health, Inc., DTR Medical Ltd, B. Braun Melsungen AG, Becton, Dickinson and Company, Olympus Corporation, Hologic Inc., Medtronic Limited, Zimmer Biomet Holdings, Inc

Lung Biopsy Systems Market Trends